As previously discussed, the combination of PD1/PD-L1 inhibitors with receptor tyrosine kinase inhibitors (RTKIs) has been shown to significantly improve outcomes in patients with ccRCC. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.